Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE.

Mediators Inflamm. 2014;2014:803095. doi: 10.1155/2014/803095. Epub 2014 Jun 1.

2.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Stramotas SA, Tracy R, Currier JS.

HIV Med. 2014 Aug;15(7):431-41. doi: 10.1111/hiv.12128. Epub 2014 Feb 10.

3.

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS.

AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.

4.

Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy.

Boger MS, Bian A, Shintani A, Milne GL, Morrow JD, Erdem H, Mitchell V, Haas DW, Hulgan T.

Antivir Ther. 2012;17(3):485-93. doi: 10.3851/IMP1990. Epub 2011 Dec 14.

5.

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team.

PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.

6.

Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen.

Tunjungputri RN, Van Der Ven AJ, Schonsberg A, Mathan TS, Koopmans P, Roest M, Fijnheer R, Groot PG, de Mast Q.

AIDS. 2014 Sep 10;28(14):2091-6. doi: 10.1097/QAD.0000000000000415.

PMID:
25265076
7.
8.

Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.

Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens MG, Kashuba AD.

Antimicrob Agents Chemother. 2013 Feb;57(2):784-8. doi: 10.1128/AAC.01826-12. Epub 2012 Nov 26.

9.

Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.

Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T.

HIV Clin Trials. 2009 May-Jun;10(3):181-92. doi: 10.1310/hct1003-181.

10.

Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F.

Antivir Ther. 2014;19(1):117-23. doi: 10.3851/IMP2691. Epub 2013 Oct 22.

PMID:
24145365
11.

Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, Podzamczer D, Burgos J, Lonca M, Domingo P, Gatell JM, Ribera E.

AIDS. 2012 Feb 20;26(4):475-81. doi: 10.1097/QAD.0b013e32834f3507.

PMID:
22112606
12.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
13.

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.

Martínez E, D'Albuquerque PM, Llibre JM, Gutierrez F, Podzamczer D, Antela A, Berenguer J, Domingo P, Moreno X, Perez I, Pich J, Gatell JM; SPIRAL Trial Group.

AIDS. 2012 Nov 28;26(18):2315-26. doi: 10.1097/QAD.0b013e328359f29c.

PMID:
23018438
14.

Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.

Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M.

PLoS One. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014.

15.

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05).

Antivir Ther. 2011;16(6):937-40. doi: 10.3851/IMP1826.

PMID:
21900727
16.

Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.

Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.

Antivir Ther. 2003 Aug;8(4):347-54.

PMID:
14518704
17.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
18.

Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.

Calin R, Paris L, Simon A, Peytavin G, Wirden M, Schneider L, Valantin MA, Tubiana R, Agher R, Katlama C.

Antivir Ther. 2012;17(8):1601-4. doi: 10.3851/IMP2344. Epub 2012 Sep 3.

PMID:
22941896
19.

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).

Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28.

PMID:
24161018
20.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk